AR125379A1 - Un fab anti-tslp con estabilidad mejorada - Google Patents
Un fab anti-tslp con estabilidad mejoradaInfo
- Publication number
- AR125379A1 AR125379A1 ARP220101003A ARP220101003A AR125379A1 AR 125379 A1 AR125379 A1 AR 125379A1 AR P220101003 A ARP220101003 A AR P220101003A AR P220101003 A ARP220101003 A AR P220101003A AR 125379 A1 AR125379 A1 AR 125379A1
- Authority
- AR
- Argentina
- Prior art keywords
- fab
- tslp
- vector
- improved stability
- nucleic acid
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a un Fab anti-TSLP con estabilidad mejorada, a ácidos nucleicos que codifican dicho Fab, a células hospedadoras y a un vector que comprende dichos ácidos nucleicos, y a métodos para utilizar dicho Fab en el tratamiento de afecciones relacionadas con la TSLP. Reivindicación 1: Un Fab que comprende una cadena pesada que comprende la secuencia de aminoácidos expuesta en la SEQ ID Nº 1 y una cadena ligera que comprende la secuencia de aminoácidos expuesta en la SEQ ID Nº 2. Reivindicación 8: Una composición farmacéutica que comprende el Fab de una cualquiera de las reivindicaciones 1 a 7. Reivindicación 9: Un ácido nucleico que codifica el Fab de cualquiera de las reivindicaciones 1 a 7. Reivindicación 10: Un vector que comprende el ácido nucleico de la reivindicación 9. Reivindicación 11: Una célula hospedadora que comprende el ácido nucleico de la reivindicación 9 o el vector de la reivindicación 10.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169183 | 2021-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125379A1 true AR125379A1 (es) | 2023-07-12 |
Family
ID=75588042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101003A AR125379A1 (es) | 2021-04-19 | 2022-04-19 | Un fab anti-tslp con estabilidad mejorada |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4326767A1 (es) |
| JP (1) | JP2024516962A (es) |
| KR (1) | KR20230172508A (es) |
| CN (1) | CN117222665A (es) |
| AR (1) | AR125379A1 (es) |
| AU (1) | AU2022263281A1 (es) |
| BR (1) | BR112023021587A2 (es) |
| CA (1) | CA3216894A1 (es) |
| CL (1) | CL2023003082A1 (es) |
| CO (1) | CO2023015286A2 (es) |
| EC (1) | ECSP23086870A (es) |
| IL (1) | IL307651A (es) |
| TW (1) | TW202306982A (es) |
| WO (1) | WO2022223514A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| CN113423733B (zh) * | 2019-09-04 | 2023-09-22 | 正大天晴药业集团股份有限公司 | 结合tslp的抗体及其用途 |
| BR112022008031A2 (pt) * | 2019-10-28 | 2022-07-12 | Medimmune Ltd | Formulações de pó seco de anticorpos de ligação à linfopoietina estromal tímica (tslp) e métodos de uso das mesmas |
-
2022
- 2022-04-19 BR BR112023021587A patent/BR112023021587A2/pt unknown
- 2022-04-19 TW TW111114769A patent/TW202306982A/zh unknown
- 2022-04-19 AR ARP220101003A patent/AR125379A1/es unknown
- 2022-04-19 KR KR1020237038201A patent/KR20230172508A/ko unknown
- 2022-04-19 CA CA3216894A patent/CA3216894A1/en active Pending
- 2022-04-19 IL IL307651A patent/IL307651A/en unknown
- 2022-04-19 AU AU2022263281A patent/AU2022263281A1/en active Pending
- 2022-04-19 JP JP2023563876A patent/JP2024516962A/ja active Pending
- 2022-04-19 EP EP22724429.0A patent/EP4326767A1/en active Pending
- 2022-04-19 CN CN202280029099.0A patent/CN117222665A/zh active Pending
- 2022-04-19 WO PCT/EP2022/060236 patent/WO2022223514A1/en active Application Filing
-
2023
- 2023-10-17 CL CL2023003082A patent/CL2023003082A1/es unknown
- 2023-11-14 CO CONC2023/0015286A patent/CO2023015286A2/es unknown
- 2023-11-16 EC ECSENADI202386870A patent/ECSP23086870A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23086870A (es) | 2023-12-29 |
| CN117222665A (zh) | 2023-12-12 |
| IL307651A (en) | 2023-12-01 |
| BR112023021587A2 (pt) | 2023-12-19 |
| CO2023015286A2 (es) | 2024-02-05 |
| EP4326767A1 (en) | 2024-02-28 |
| CA3216894A1 (en) | 2022-10-27 |
| CL2023003082A1 (es) | 2024-04-19 |
| WO2022223514A1 (en) | 2022-10-27 |
| KR20230172508A (ko) | 2023-12-22 |
| AU2022263281A9 (en) | 2023-11-16 |
| AU2022263281A1 (en) | 2023-11-09 |
| JP2024516962A (ja) | 2024-04-18 |
| TW202306982A (zh) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039003A1 (es) | Composiciones y metodos para alterar el contenido de tocotrienoles | |
| ES2531290T3 (es) | Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas | |
| BR112017008108A2 (pt) | incorporação de aminoácidos não naturais em proteínas | |
| BR112012033699A2 (pt) | polipeptídeo tendo atividade beta-glicosidase e seus usos | |
| PE20180743A1 (es) | Metodo para produccion de l-aminoacido | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| AR110093A1 (es) | D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma | |
| AR114960A1 (es) | Proteína tolerante a herbicida, gen codificante y uso de la misma | |
| AR070693A1 (es) | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas a partir de la expresion del polipeptido de nitrato 2 (nrt2) | |
| AR080339A1 (es) | Plantas que tienen modificada la expresion de gdh con mejores rasgos relacionados con el rendimiento y un metodo para producirlas | |
| AR071232A1 (es) | Proteina hibrida usada como vacuna contra toxinas shiga de e. coli | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| AR100606A1 (es) | Variantes de lipasas y polinucleótidos que las codifican | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| BR112014022467A2 (pt) | transformantes de rasamsonia | |
| BRPI0410562A (pt) | molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo | |
| ES2483916T3 (es) | RHD6 y su uso en la modulación del desarrollo del pelo radicular en plantas | |
| AR087719A2 (es) | Celula de planta transformada, cultivo de tejidos y planta transgenica | |
| BR112012033701A2 (pt) | polipeptídeo tendo atividade de degradação de carbohidrato e seus usos | |
| AR125379A1 (es) | Un fab anti-tslp con estabilidad mejorada | |
| AR085824A1 (es) | Anticuerpo anti-receptor il-3 humano | |
| AR127562A1 (es) | ANTICUERPOS CONTRA EL FACTOR DE NECROSIS TUMORAL a HUMANO | |
| AR107900A1 (es) | Un gen de síntesis de tentoxina, un método para producir tentoxina o dihidrotentoxina usando el gen, y un transformante que lo comprende | |
| MX2022008298A (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. | |
| BR0303362A (pt) | Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal |